ReviewFrontiers in pharmacology2022
Pharmacological Treatment of Secondary Lymphedema.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 39 citations in OpenAlex.
- Effects of monoglucosyl hesperidin on human lymphatic circulatory function: A randomized placebo-controlled, double-blind, crossover trial.Scientific reports · 2026Trial
- Efficacy of Intensified Hygiene Measures with or without the Addition of Doxycycline in the Management of Filarial Lymphedema: A Randomized Double-Blind, Placebo-Controlled Clinical Trial in Tanzania.The American journal of tropical medicine and hygiene · 2024Trial
- Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Alleviates Secondary Lymphedema via Inhibiting TGFβ/SMAD2/3 Signaling Pathway.bioRxiv : the preprint server for biology · 2026Article
- Keratinocytes: A key player in skin immunity and their emerging roles in secondary lymphedema.JID innovations : skin science from molecules to population health · 2026Review
- Breast Cancer-Related Lymphedema: Nursing-Led Strategies - A Narrative Review.Journal of multidisciplinary healthcare · 2026Review
- Lymphedema: current treatment strategies and future directions in tissue engineering.Frontiers in medicine · 2026Review
- Article
- Technology-enhanced compression and AI-integrated lymphedema care: a narrative review.Irish journal of medical science · 2025Review
- Decellularized lymph node scaffolds accelerate restoration of lymphatic drainage in rat hind limb lymphedema.Bioengineering & translational medicine · 2025Article
- Vitamins, Vascular Health and Disease.Nutrients · 2025Review
- Tissue engineering approaches for lymphedema: biomaterial innovations and clinical potential.Frontiers in cell and developmental biology · 2025Review
- The role of exercise in promoting lymphangiogenesis and extracellular matrix synthesis in lymphedema-induced tissue injury.Molecular biology reports · 2024Article
- Ultrasound Irradiation as a Candidate Procedure to Improve the Transdermal Drug Delivery to the Tail Edema of a Mouse Model.International journal of molecular sciences · 2024Article
- Overview of Lymphatic Muscle Cells in Development, Physiology, and Disease.Microcirculation (New York, N.Y. : 1994) · 2024Review
- Incidence of lymphedema related to various cancers.Medical oncology (Northwood, London, England) · 2024Review
- Quantification of Lymphangiogenesis in the Murine Lymphedema Tail Model Using Intravital Microscopy.Lymphatic research and biology · 2024Article
- Topical tissue nanotransfection ofMolecular therapy. Nucleic acids · 2024Article
- Evaluation of Primary Lymphedema with Intranodal Lymphangiography.Cardiovascular and interventional radiology · 2024Observational
- Molecular pathophysiology of secondary lymphedema.Frontiers in cell and developmental biology · 2024Review
- TRPML1 acts as a predisposing factor in lymphedema development by regulating the subcellular localization of aquaporin-3, -5.PloS one · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Lymphedema is a chronic disease that results in swelling and decreased function due to abnormal lymphatic fluid clearance and chronic inflammation. In Western countries, lymphedema most commonly develops following an iatrogenic injury to the lymphatic system during cancer treatment. It is estimated that as many as 10 million patients suffer from lymphedema in the United States alone. Current treatments for lymphedema are palliative in nature, relying on compression garments and physical therapy to decrease interstitial fluid accumulation in the affected extremity. However, recent discoveries have increased the hopes of therapeutic interventions that may promote lymphatic regeneration and function. The purpose of this review is to summarize current experimental pharmacological strategies in the treatment of lymphedema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.